New Tests for Assessing Non-Inferiority and Equivalence from Survival Data
نویسنده
چکیده
We propose a new nonparametric method for assessing non-inferiority of an experimental therapy compared to a standard of care. The ratio E R of true median survival times is the parameter of interest. This is of considerable interest in clinical trials of generic drugs. We think of the ratio E R m m of the sample medians as a point estimate of the ratio E R . We use the Fieller-Hinkley distribution of the ratio of two normally distributed random variables to derive an unbiased level-α test of inferiority null hypothesis, which is stated in terms of the ratio E R and a pre-specified fixed non-inferiority margin δ. We also explain how to assess equivalence and non-inferiority using bootstrap equivalent confidence intervals on the ratio E R . The proposed new test does not require the censoring distributions for the two arms to be equal and it does not require the hazard rates to be proportional. If the proportional hazards assumption holds good, the proposed new test is more attractive. We also discuss sample size determination. We claim that our test procedure is simple and attains adequate power for moderate sample sizes. We extend the proposed test procedure to stratified analysis. We propose a “two one-sided tests” approach for assessing equivalence.
منابع مشابه
A unifying approach to non-inferiority, equivalence and superiority tests via multiple decision processes.
Two approaches of multiple decision processes are proposed for unifying the non-inferiority, equivalence and superiority tests in a comparative clinical trial for a new drug against an active control. One is a method of confidence set with confidence coefficient 0.95 improving the conventional 0.95 confidence interval in the producer's risk and also the consumer's risk in some cases. It require...
متن کاملMethodological standards in non-inferiority AIDS trials: moving from adherence to compliance
BACKGROUND The interpretation of the results of active-control trials regarding the efficacy and safety of a new drug is important for drug registration and following clinical use. It has been suggested that non-inferiority and equivalence studies are not reported with the same quantitative rigor as superiority studies. METHODS Standard methodological criteria for non-inferiority and equivale...
متن کاملEquivalence and non inferiority trials
Many effective drugs, biologics and devices exist. Because of this, it is often considered unethical to undertake placebo controlled clinical trials to evaluate new treatments. Rather, randomized active control noninferiority trials have become the norm. These trials, however, are accompanied by serious issues including selecting an active comparator, identifying previously run active comparato...
متن کامل